{"id":53,"date":"2022-01-24T12:13:39","date_gmt":"2022-01-24T03:13:39","guid":{"rendered":"https:\/\/e-nabio.co.jp\/en\/?page_id=53"},"modified":"2022-04-04T17:53:11","modified_gmt":"2022-04-04T08:53:11","slug":"science","status":"publish","type":"page","link":"https:\/\/e-nabio.co.jp\/en\/science\/","title":{"rendered":"SCIENCE"},"content":{"rendered":"<div class=\"science_page\">\r\n  <div class=\"page_inner\">\r\n    <div class=\"width_adjust\">\r\n      <div class=\"mokuji_box\">\r\n        <h2>Our Pipeline and Core (Nucleic Acid Modification) Technologies<\/h2>\r\n        <ul class=\"mokuji_ul\">\r\n          <li>\r\n            <a href=\"#sci01\">Pipeline 1: Unmet early-stage bladder cancer<\/a>\r\n          <\/li>\r\n          <li>\r\n            <a href=\"#sci02\">Pipeline 2: Unresectable KRAS-mutated colorectal cancer<\/a>\r\n          <\/li>\r\n          <li>\r\n            <a href=\"#sci04\">Core (nucleic acid modification) technology 1: Ligand cross-linking technology to oligonucleic acids<\/a>\r\n          <\/li>\r\n          <li>\r\n            <a href=\"#sci05\">Core (nucleic acid modification) technology 2: Dangling end cross-linked oligonucleic acids<\/a>\r\n          <\/li>\r\n          <li>\r\n            <a href=\"#sci03\">List of our modalities or medical seeds<\/a>\r\n          <\/li>\r\n        <\/ul>\r\n      <\/div>\r\n      <ul class=\"science_ul\">\r\n        <li id=\"sci01\" >\r\n          <div class=\"li_inner\">\r\n            <div class=\"item\"><img decoding=\"async\" src=\"\/struct\/wp-content\/uploads\/shikyu.png\" alt=\"Pipeline 1\"><\/div>\r\n            <div class=\"item\">\r\n              <h2><span>Pipeline 1<\/span><\/h2>\r\n              <ul>\r\n                <li class=\"list_item\">Target: Unmet early-stage bladder cancer (nonmuscle invasive bladder cancer, NMIBC)<\/li>\r\n                <li class=\"list_item\">Number of eligible patients in Japan: About 10,000 per year<\/li>\r\n                <li class=\"list_item\">Seed: Chemically modified microRNA-143 (patented)<\/li>\r\n                <li class=\"list_item\">Mechanism: Mutant KRAS network suppressor molecular targeted drug<\/li>\r\n                <li class=\"list_item\">Status: Non-clinical stage preparing for PI (Physician initiated clinical trials)<\/li>\r\n              <\/ul>\r\n            <\/div>\r\n          <\/div>\r\n        <\/li>\r\n        <li id=\"sci02\">\r\n          <div class=\"li_inner\">\r\n            <div class=\"item\"><img decoding=\"async\" src=\"\/struct\/wp-content\/uploads\/ichou.png\" alt=\"Pipeline 2\"><\/div>\r\n            <div class=\"item\">\r\n              <h2><span>Pipeline 2<\/span><\/h2>\r\n              <ul>\r\n                <li class=\"list_item\">Target: Unresectable mutant KRAS colorectal cancer<\/li>\r\n                <li class=\"list_item\">Number of eligible patients in Japan: About 100,000 per year<\/li>\r\n                <li class=\"list_item\">Seed: Chemically modified microRNA-143 (patented)<\/li>\r\n                <li class=\"list_item\">Mechanism: Mutant KRAS network-suppressive molecularly targeted drug<\/li>\r\n                <li class=\"list_item\">Status: Non-clinical stage<\/li>\r\n              <\/ul>\r\n            <\/div>\r\n          <\/div>\r\n        <\/li>\r\n        <li id=\"sci04\">\r\n          <div class=\"li_inner\">\r\n            <div class=\"item\"><img decoding=\"async\" src=\"\/struct\/wp-content\/uploads\/sience01.png\" alt=\"Core (nucleic acid modification) Technology 1: Ligand cross-linking technology to oligo-nucleic acids\"><\/div>\r\n            <div class=\"item\">\r\n              <h2><span>Core (nucleic acid modification) Technology 1: Ligand cross-linking technology to oligo-nucleic acids<\/span><\/h2>\r\n              <ul>\r\n                <li class=\"list_item\">Ligand cross-linking for targeted delivery of nucleic acid (cross-linking at any location including 5' and 3' ends) <patented>.<\/li>\r\n                <li class=\"list_item\">15-minute cross-linking technique between nucleic acid and ligand<\/li>\r\n                <li class=\"list_item\">Wide range of ligands can be selected by library construction such as sugar, peptide, protein, etc.<\/li>\r\n                <li class=\"list_item\">Please ask us for more information.<\/li>\r\n              <\/ul>\r\n            <\/div>\r\n          <\/div>\r\n        <\/li>\r\n        <li id=\"sci05\">\r\n          <div class=\"li_inner\">\r\n            <div class=\"item\"><img decoding=\"async\" src=\"\/struct\/wp-content\/uploads\/sience02.png\" alt=\"Core (Nucleic Acid Modification) Technology 2: Dangling End Cross-linked Nucleic Acids\"><\/div>\r\n            <div class=\"item\">\r\n              <h2><span>Core (Nucleic Acid Modification) Technology 2: Dangling End Cross-linked Nucleic Acids<\/span><\/h2>\r\n              <ul>\r\n                <li class=\"list_item\">Dangling Ends for Improved Nuclease Resistance <patented><\/li>\r\n                <li class=\"list_item\">Can modify various oligo-nucleic acids and nucleic acid molecules<\/li>\r\n                <li class=\"list_item\">Please ask us for more information.<\/li>\r\n              <\/ul>\r\n            <\/div>\r\n          <\/div>\r\n        <\/li>\r\n        <li id=\"sci03\">\r\n          <div class=\"li_inner\">\r\n            <div class=\"item\"><img decoding=\"async\" src=\"\/struct\/wp-content\/uploads\/sience05.png\" alt=\"Our Modalities (Seeds) List\"><\/div>\r\n            <div class=\"item\">\r\n              <h2><span>Our Modalities (Seeds) List<\/span><\/h2>\r\n              <ul>\r\n                <li class=\"list_item\">Modality 1: Chemically modified microRNA-143 <patented><\/li>\r\n                <li class=\"list_item\">Modality 2: Chemically modified microRNA-145 <patented><\/li>\r\n                <li class=\"list_item\">Exploration of other modalities: Highly modified microRNA derivatives\r\n                  <ul>\r\n                    <li>Target diseases: Solid tumors (melanoma), refractory cancers such as pancreatic cancer and breast cancer, blood cancers<\/li>\r\n                    <li>Discovery of microRNAs relevant to the treatment of neurological and cardiac diseases<\/li>\r\n                    <li>Prophylactic drug discovery: Search for microRNAs related to longevity of health<\/li>\r\n                    <li>Companion animal's drug development: Providing options in veterinary medicine where few therapies are available (e.g., canine oral cancer (melanoma))<\/li>\r\n                  <\/ul>\r\n                <\/li>\r\n              <\/ul>\r\n            <\/div>\r\n          <\/div>\r\n        <\/li>\r\n      <\/ul>\r\n    <\/div>\r\n  <\/div>\r\n<\/div>\r\n","protected":false},"excerpt":{"rendered":"Our Pipeline and Core (Nucleic Acid Modification) Technologies Pipeline 1: Unmet early-stage bladder cancer Pi ...","protected":false},"author":2,"featured_media":244,"parent":0,"menu_order":20,"comment_status":"closed","ping_status":"closed","template":"page-nosidebar-fullwidththumb-h1.php","meta":{"_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"footnotes":""},"class_list":["post-53","page","type-page","status-publish","has-post-thumbnail","hentry"],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/e-nabio.co.jp\/en\/wp-json\/wp\/v2\/pages\/53","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/e-nabio.co.jp\/en\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/e-nabio.co.jp\/en\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/e-nabio.co.jp\/en\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/e-nabio.co.jp\/en\/wp-json\/wp\/v2\/comments?post=53"}],"version-history":[{"count":14,"href":"https:\/\/e-nabio.co.jp\/en\/wp-json\/wp\/v2\/pages\/53\/revisions"}],"predecessor-version":[{"id":256,"href":"https:\/\/e-nabio.co.jp\/en\/wp-json\/wp\/v2\/pages\/53\/revisions\/256"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/e-nabio.co.jp\/en\/wp-json\/wp\/v2\/media\/244"}],"wp:attachment":[{"href":"https:\/\/e-nabio.co.jp\/en\/wp-json\/wp\/v2\/media?parent=53"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}